Tag: painful diabetic neuropathy
Education and collaboration key to continued advancement of painful diabetic neuropathy...
The neuromodulation space has proliferated significantly over the past few years, and one area in which this is most notable is with the expansion...
Abbott gains US FDA approval for SCS therapy in painful diabetic...
Abbott has announced that the US Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful...
Neuralace enrols first patients in AT-PDN study evaluating Axon therapy
Neuralace Medical has announced the commencement of and first patient enrolments in its AT-PDN (Axon therapy and painful diabetic neuropathy) study.
The multicentre AT-PDN study...
Nevro announces positive coverage updates for treatment of painful diabetic neuropathy...
Nevro Corporation has announced that US health plan Aetna has updated its spinal cord stimulation (SCS) coverage policy to explicitly cover painful diabetic neuropathy...
High-frequency SCS demonstrates “substantial improvement” in health-related quality of life outcomes
Nevro Corporation has announced that the complete 12-month results from the SENZA-PDN randomised controlled trial (RCT), including health-related quality of life outcomes in patients with...
High responder rates, substantial pain relief and no explants among key...
Nevro Corporation has announced the results from data presentations at the American Diabetes Association (ADA) 82nd Scientific Sessions (3–7 June 2022, New Orleans, USA) supporting the use of...
Nevro announces upcoming presentation of new SENZA-PDN clinical data
Nevro Corporation has announced that data from the SENZA painful diabetic neuropathy (PDN) randomised controlled trial (RCT)—which the company says is the largest RCT to...
NANS 2022: New 18-month data show durability of high-frequency SCS for...
This year’s North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) saw 18-month data from SENZA-PDN—a randomised controlled trial (RCT) evaluating the...
Nevro announces clinical data reinforcing significant and durable benefits of 10kHz...
Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...
Nevro announces three key data publications on novel painful diabetic neuropathy...
Nevro has announced three clinical data publications on treating painful diabetic neuropathy (PDN) with 10kHz spinal cord stimulation (SCS) therapy—including 12-month data from the...
